Published in Gastroenterology on November 02, 2011
Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. Hepatology (2012) 1.77
Cytoplasmic tyrosine phosphatase Shp2 coordinates hepatic regulation of bile acid and FGF15/19 signaling to repress bile acid synthesis. Cell Metab (2014) 1.54
Intestine-specific deletion of SIRT1 in mice impairs DCoH2-HNF-1α-FXR signaling and alters systemic bile acid homeostasis. Gastroenterology (2013) 1.50
Farnesoid X receptor-induced lysine-specific histone demethylase reduces hepatic bile acid levels and protects the liver against bile acid toxicity. Hepatology (2015) 1.45
Fibroblast Growth Factor Signaling Controls Liver Size in Mice With Humanized Livers. Gastroenterology (2015) 1.44
Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J Hepatol (2012) 1.30
Promotion of liver regeneration/repair by farnesoid X receptor in both liver and intestine in mice. Hepatology (2012) 1.04
PPARα-UGT axis activation represses intestinal FXR-FGF15 feedback signalling and exacerbates experimental colitis. Nat Commun (2014) 0.94
Nuclear receptors as drug targets in cholestatic liver diseases. Clin Liver Dis (2013) 0.91
Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat Rev Drug Discov (2015) 0.90
Hepatobiliary manifestations of ulcerative colitis: an example of gut-liver crosstalk. Gastroenterol Rep (Oxf) (2014) 0.87
A pleiotropic role for the orphan nuclear receptor small heterodimer partner in lipid homeostasis and metabolic pathways. J Lipids (2012) 0.87
Clinical application of transcriptional activators of bile salt transporters. Mol Aspects Med (2013) 0.87
Bile acid signaling and liver regeneration. Biochim Biophys Acta (2014) 0.85
Impact of new-generation lipid emulsions on cellular mechanisms of parenteral nutrition-associated liver disease. Adv Nutr (2014) 0.85
Expression of hepatic Fibroblast Growth Factor 19 is enhanced in Primary Biliary Cirrhosis and correlates with severity of the disease. Sci Rep (2015) 0.84
Autologous intestinal reconstruction surgery as part of comprehensive management of intestinal failure. Pediatr Surg Int (2015) 0.81
FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation. World J Gastroenterol (2014) 0.81
Treatment of autoimmune liver disease: current and future therapeutic options. Ther Adv Chronic Dis (2013) 0.81
Nod2 deficiency protects mice from cholestatic liver disease by increasing renal excretion of bile acids. J Hepatol (2014) 0.80
Recent advances in understanding and managing cholestasis. F1000Res (2016) 0.79
Hepatic expression of detoxification enzymes is decreased in human obstructive cholestasis due to gallstone biliary obstruction. PLoS One (2015) 0.79
Intestinal nuclear bile acid receptor FXR and cholestasis. Ann Hepatol (2011) 0.78
Digestive physiology of the pig symposium: intestinal bile acid sensing is linked to key endocrine and metabolic signaling pathways. J Anim Sci (2013) 0.78
Untargeted Metabolomics Reveals Dose-Response Characteristics for Effect of Rhubarb in a Rat Model of Cholestasis. Front Pharmacol (2016) 0.77
FXR-induced secretion of FGF15/19 inhibits CYP27 expression in cholangiocytes through p38 kinase pathway. Pflugers Arch (2013) 0.77
Intestinal nuclear receptors in HDL cholesterol metabolism. J Lipid Res (2014) 0.77
Simultaneous bile duct and portal vein ligation induces faster atrophy/hypertrophy complex than portal vein ligation: role of bile acids. Sci Rep (2015) 0.76
Restoration of enterohepatic bile acid pathways in pregnant mice following short term activation of Fxr by GW4064. Toxicol Appl Pharmacol (2016) 0.76
Bile acid homeostasis controls CAR signaling pathways in mouse testis through FXRalpha. Sci Rep (2017) 0.75
Altered systemic bile acid homeostasis contributes to liver disease in pediatric patients with intestinal failure. Sci Rep (2016) 0.75
Farnesoid X Receptor Agonist Treatment Alters Bile Acid Metabolism but Exacerbates Liver Damage in a Piglet Model of Short-Bowel Syndrome. Cell Mol Gastroenterol Hepatol (2017) 0.75
Critical role of RanBP2-mediated SUMOylation of Small Heterodimer Partner in maintaining bile acid homeostasis. Nat Commun (2016) 0.75
Impaired Hepatic Adaptation to Chronic Cholestasis induced by Primary Sclerosing Cholangitis. Sci Rep (2016) 0.75
Farnesoid X Receptor an Emerging Target to Combat Obesity. Dig Dis (2017) 0.75
Fibroblast growth factor 19, an anticholestatic drug produced by human liver. Gastroenterology (2012) 0.75
The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol (2017) 0.75
Engineered fibroblast growth factor 19 protects from acetaminophen-induced liver injury and stimulates aged liver regeneration in mice. Cell Death Dis (2017) 0.75
Differential regulation of intestinal efflux transporters by pregnancy in mice. Xenobiotica (2017) 0.75
Bile Acid Uptake Transporters as Targets for Therapy. Dig Dis (2017) 0.75
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab (2005) 9.14
FAPPs control Golgi-to-cell-surface membrane traffic by binding to ARF and PtdIns(4)P. Nat Cell Biol (2004) 4.85
Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology (2006) 4.70
Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest (2004) 4.65
Sex-specific prevalence of adenomas, advanced adenomas, and colorectal cancer in individuals undergoing screening colonoscopy. JAMA (2011) 4.21
ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-α and PGC-1. Nat Med (2011) 3.96
Adipose triglyceride lipase contributes to cancer-associated cachexia. Science (2011) 3.70
Glycosphingolipid synthesis requires FAPP2 transfer of glucosylceramide. Nature (2007) 3.13
Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A (2006) 3.05
Sedation in screening colonoscopy: impact on quality indicators and complications. Am J Gastroenterol (2012) 2.97
Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol (2012) 2.93
Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol (2013) 2.85
Cholesterol gallstone disease. Lancet (2006) 2.83
REV-ERBalpha participates in circadian SREBP signaling and bile acid homeostasis. PLoS Biol (2009) 2.76
Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology (2002) 2.64
The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology (2013) 2.63
Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut (2011) 2.57
CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology (2005) 2.45
von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. Hepatology (2012) 2.36
Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial. J Am Coll Cardiol (2012) 2.11
Identification of a hormonal basis for gallbladder filling. Nat Med (2006) 2.03
Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology (2004) 2.02
Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am J Pathol (2009) 1.87
The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol (2011) 1.87
Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. J Hepatol (2003) 1.85
Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology (2005) 1.84
Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut (2012) 1.83
Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis (2010) 1.79
Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. Gastroenterology (2003) 1.79
Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma. Hepatology (2013) 1.77
The biogenesis of the Golgi ribbon: the roles of membrane input from the ER and of GM130. Mol Biol Cell (2007) 1.74
Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice. Hepatology (2009) 1.72
Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Mol Pharm (2006) 1.72
Bile acids trigger cholemic nephropathy in common bile-duct-ligated mice. Hepatology (2013) 1.71
A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis. Am J Pathol (2007) 1.70
Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection. Clin Gastroenterol Hepatol (2011) 1.70
Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation. Hepatology (2014) 1.68
Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids. Am J Physiol Gastrointest Liver Physiol (2005) 1.64
Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. Am J Physiol Gastrointest Liver Physiol (2006) 1.63
Oxidative stress-induced risk factors associated with the metabolic syndrome: a unifying hypothesis. J Nutr Biochem (2007) 1.62
Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol (2005) 1.62
Nuclear bile acid receptor FXR protects against intestinal tumorigenesis. Cancer Res (2008) 1.61
Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. Curr Med Chem (2006) 1.60
Expression of ABCG5 and ABCG8 is required for regulation of biliary cholesterol secretion. J Biol Chem (2004) 1.57
Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim Biophys Acta (2006) 1.57
24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology (2006) 1.54
Deciphering the nuclear bile acid receptor FXR paradigm. Nucl Recept Signal (2010) 1.53
Role of hepatic phospholipids in development of liver injury in Mdr2 (Abcb4) knockout mice. Liver Int (2008) 1.52
Growth hormone resistance exacerbates cholestasis-induced murine liver fibrosis. Hepatology (2015) 1.49
The arachidonic acid metabolome serves as a conserved regulator of cholesterol metabolism. Cell Metab (2014) 1.47
Oncosis represents the main type of cell death in mouse models of cholestasis. J Hepatol (2005) 1.46
Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol (2003) 1.45
FGF19 signaling cascade suppresses APOA gene expression. Arterioscler Thromb Vasc Biol (2012) 1.43
Serum Bile Acid Levels in Children With Nonalcoholic Fatty Liver Disease. J Pediatr Gastroenterol Nutr (2015) 1.42
Sedlin controls the ER export of procollagen by regulating the Sar1 cycle. Science (2012) 1.41
Esomeprazole-induced central fever with severe myalgia. Ann Pharmacother (2005) 1.41
Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol (2003) 1.41
Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling. Liver Int (2013) 1.40
Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia. J Lipid Res (2008) 1.36
Acetylation dynamics and stoichiometry in Saccharomyces cerevisiae. Mol Syst Biol (2014) 1.35
Nuclear receptors in liver disease. Hepatology (2011) 1.34
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis (2012) 1.33
FXR agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid malabsorption. J Lipid Res (2007) 1.31
Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. Am J Pathol (2006) 1.30
Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J Hepatol (2012) 1.30
Mechanisms of disease: mechanisms and clinical implications of cholestasis in sepsis. Nat Clin Pract Gastroenterol Hepatol (2006) 1.27
Liver dysfunction and phosphatidylinositol-3-kinase signalling in early sepsis: experimental studies in rodent models of peritonitis. PLoS Med (2012) 1.27
Mechanisms of cholestasis. Clin Liver Dis (2008) 1.24
Peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC1alpha) is a metabolic regulator of intestinal epithelial cell fate. Proc Natl Acad Sci U S A (2011) 1.23
New molecular insights into the mechanisms of cholestasis. J Hepatol (2009) 1.23
Coordinate regulation of gallbladder motor function in the gut-liver axis. Hepatology (2008) 1.22
Fxr(-/-) mice adapt to biliary obstruction by enhanced phase I detoxification and renal elimination of bile acids. J Lipid Res (2005) 1.22
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci (2010) 1.22
OCRL controls trafficking through early endosomes via PtdIns4,5P₂-dependent regulation of endosomal actin. EMBO J (2011) 1.21
Intestinal specific LXR activation stimulates reverse cholesterol transport and protects from atherosclerosis. Cell Metab (2010) 1.20